Business
Merck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results; Highlights Progress Advancing Broad, Diverse Pipeline
RAHWAY, N.J., February 03, 2026--Merck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results
About this update from Merck & Company, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":217,"url":"https://media.zenfs.com/en/business-wire.com/0426366bbc96fe6570974d728ef1f09a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/8LhBwXOC3bUZ5fNfz7Z25w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQzNDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/0426366bbc96fe6570974d728ef1f09a","width":480,"height":217}},"lazy":false},{"type":"text","content":"Reports Strength in Oncology and Animal Health, Plus Increasing Contributions From WINREVAIR and CAPVAXIVE","length":106,"tagName":"p","attribs":{}},{"type":"list","items":[{"val":[{"type":"text","content":"Fourth-Quarter Worldwide Sales Were $16.4 Billion (5% Growth; 4% Growth ex-FX)","length":78,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Fourth-Quarter GAAP EPS Was $1.19; Non-GAAP EPS Was $2.04; GAAP and Non-GAAP EPS Include a Charge of $0.05 per Share for the Acquisition of MK-8690 Sole Global Rights","length":166,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Full-Year Worldwide Sales Were $65.0 Billion (1% Growth; 2% Growth ex-FX)","length":73,"tagName":"p","attribs":{}},{"type":"list","items":[{"val":[{"type":"text","content":"KEYTRUDA/KEYTRUDA QLEX Sales Were $31.7 Billion (7% Growth Both Nominally and ex-FX); Includes KEYTRUDA QLEX Sales of $40 Million","length":129,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"WINREVAIR Sales Were $1.4 Billion","length":33,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"CAPVAXIVE Sales Were $759 Million","length":33,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"GARDASIL/GARDASIL 9 Sales Were $5.2 Billion (39% Decline Both Nominally and ex-FX)","length":82,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Animal Health Sales Were $6.4 Billion (8% Growth; 9% Growth ex-FX)","length":66,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":343,"olType":false}]},{"val":[{"type":"text","content":"Full-Year 2025 GAAP EPS Was $7.28; Non-GAAP EPS Was $8.98; GAAP and Non-GAAP EPS Include Charges of $0.20 per Share Related to Certain Business Development Transactions","length":168,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Announced Positive Late-Stage Trial...